EPISODE · Dec 14, 2017 · 8 MIN
Crispr Therapeutics Plans Its First Clinical Trial for Genetic Disease
from Science, Spoken · host SpokenLayer
In late 2012, French microbiologist Emmanuelle Charpentier approached a handful of American scientists about starting a company, a Crispr company. They included UC Berkeley’s Jennifer Doudna, George Church at Harvard University, and his former postdoc Feng Zhang of the Broad Institute—the brightest stars in the then-tiny field of Crispr research. Back then barely 100 papers had been published on the little-known guided DNA-cutting system. It certainly hadn’t attracted any money. Learn about your ad choices: dovetail.prx.org/ad-choices
What this episode covers
In late 2012, French microbiologist Emmanuelle Charpentier approached a handful of American scientists about starting a company, a Crispr company. They included UC Berkeley’s Jennifer Doudna, George Church at Harvard University, and his former postdoc Feng Zhang of the Broad Institute—the brightest stars in the then-tiny field of Crispr research. Back then barely 100 papers had been published on the little-known guided DNA-cutting system. It certainly hadn’t attracted any money.
NOW PLAYING
Crispr Therapeutics Plans Its First Clinical Trial for Genetic Disease
No transcript for this episode yet
Similar Episodes
No similar episodes found.